Global Geographic Atrophy Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Geographic Atrophy Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that causes a continuous progressive degeneration of the macula. The condition is characterized by widespread atrophy of the outer retinal tissue, retinal pigment epithelium, and choriocapillaris. It typically starts in the perifoveal region and develops to the fovea over time and causing central scotomas and permanent vision loss. Various drugs and treatments are under evaluation.
Geographic Atrophy report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Geographic Atrophy market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Late-stage (Phase III) and Phase II are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Geographic Atrophy industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Geographic Atrophy key companies include Apellis Pharmaceuticals, Iveric Bio, Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Gyroscope Therapeutics, Regenerative Patch Technologies and Roche, etc. Apellis Pharmaceuticals, Iveric Bio, Alkeus Pharmaceuticals are top 3 players and held % share in total in 2022.
Geographic Atrophy can be divided into Above 60 Years and Above 75 Years, etc. Above 60 Years is the mainstream product in the market, accounting for % share globally in 2022.
Geographic Atrophy is widely used in various fields, such as Late-stage (Phase III), Phase II, Phase I and Pre-clinical stage, etc. Late-stage (Phase III) provides greatest supports to the Geographic Atrophy industry development. In 2022, global % share of Geographic Atrophy went into Late-stage (Phase III) filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Geographic Atrophy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Apellis Pharmaceuticals
Iveric Bio
Alkeus Pharmaceuticals
Hemera Biosciences
Allegro Ophthalmics
Stealth BioTherapeutics
Gyroscope Therapeutics
Regenerative Patch Technologies
Roche
Gensight Biologics
NGM Biopharmaceuticals
AstraZeneca
Lineage Cell Therapeutics
Allergan
Segment by Type
Above 60 Years
Above 75 Years
Late-stage (Phase III)
Phase II
Phase I
Pre-clinical stage
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Geographic Atrophy market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Geographic Atrophy introduction, etc. Geographic Atrophy Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Geographic Atrophy market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Geographic Atrophy report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Geographic Atrophy market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Late-stage (Phase III) and Phase II are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Geographic Atrophy industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Geographic Atrophy key companies include Apellis Pharmaceuticals, Iveric Bio, Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Gyroscope Therapeutics, Regenerative Patch Technologies and Roche, etc. Apellis Pharmaceuticals, Iveric Bio, Alkeus Pharmaceuticals are top 3 players and held % share in total in 2022.
Geographic Atrophy can be divided into Above 60 Years and Above 75 Years, etc. Above 60 Years is the mainstream product in the market, accounting for % share globally in 2022.
Geographic Atrophy is widely used in various fields, such as Late-stage (Phase III), Phase II, Phase I and Pre-clinical stage, etc. Late-stage (Phase III) provides greatest supports to the Geographic Atrophy industry development. In 2022, global % share of Geographic Atrophy went into Late-stage (Phase III) filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Geographic Atrophy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Apellis Pharmaceuticals
Iveric Bio
Alkeus Pharmaceuticals
Hemera Biosciences
Allegro Ophthalmics
Stealth BioTherapeutics
Gyroscope Therapeutics
Regenerative Patch Technologies
Roche
Gensight Biologics
NGM Biopharmaceuticals
AstraZeneca
Lineage Cell Therapeutics
Allergan
Segment by Type
Above 60 Years
Above 75 Years
Segment by Application
Late-stage (Phase III)
Phase II
Phase I
Pre-clinical stage
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Geographic Atrophy market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Geographic Atrophy introduction, etc. Geographic Atrophy Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Geographic Atrophy market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices